Vipivotide tetraxetan, also known as PSMA-617, is a highly potent prostate-specific membrane antigen (PSMA). This innovative compound is meticulously designed with three key components: the selective pharmacophore Glutamate-urea-Lysine, the versatile chelator DOTA capable of complexing with both 68Ga and 177Lu, and a linker that seamlessly connects these elements. The Glutamate-urea-Lysine component ensures precise targeting of PSMA, making it an ideal candidate for both imaging and therapeutic applications in prostate cancer.
Currently, Vipivotide tetraxetan is being investigated in clinical trials, including a Phase 2 study for metastatic castration-resistant prostate cancer, highlighting its promise in advancing prostate cancer treatment.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Vipivotide tetraxetan, PSMA617 TFA, DKFZ-PSMA-617 |
|---|---|
| IUPAC Name | (2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4, 7, 10-tris(carboxymethyl)-1, 4, 7, 10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid |
| CAS | 1702967-37-0 |
| Molecular Weight | 1042.1 |
| Molecular Formula | C49H71N9O16 |
| SMILES | C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O |